kras

Documents about kras

• Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma#249613ClinicalTrials.gov
• A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors#234504ClinicalTrials.gov
• TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors#892353ClinicalTrials.gov
• CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors#332808ClinicalTrials.gov
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations#838499ClinicalTrials.gov
• Studying Pathways of Resistance in KRAS-driven Cancers#854674ClinicalTrials.gov
• A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors#907054ClinicalTrials.gov
• Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations#993142ClinicalTrials.gov
• Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors#201612ClinicalTrials.gov
• Targeting WFS1 overcomes KRAS(G12D) dependency and adaptive resistance to KRAS inhibition in pancreatic cancer.#298906NCBI PubMed Central
• Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer#347596Harvard DASH
• Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis#215395HAL (France)
• A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.#863551ClinicalTrials.gov
• A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation#843941ClinicalTrials.gov
• KRAS, NRAS and BRAF Mutational Landscape in Serbian Early-Onset Colorectal Cancer Patients#237861Zenodo (CERN)
• Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors#426642ClinicalTrials.gov
• Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.#967257ClinicalTrials.gov
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1#910648ClinicalTrials.gov
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors#803150ClinicalTrials.gov
• KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors#414486ClinicalTrials.gov
• Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations#833525ClinicalTrials.gov
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer#855256ClinicalTrials.gov
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors#1009508ClinicalTrials.gov
• Targeted therapy in pancreatic ductal adenocarcinoma: current advances and challenges#667087ULRR
• IRE1alpha–XBP1s signaling links lipid homeostasis to hypoxic maladaptation and KRAS inhibitor responses in pancreatic ductal adenocarcinoma#929192ScholarlyCommons
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)#807635ClinicalTrials.gov
• Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer#831982ClinicalTrials.gov
• Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)#982408ClinicalTrials.gov
• A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers#890403ClinicalTrials.gov
• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors#1008188ClinicalTrials.gov
• Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation#806666ClinicalTrials.gov
• A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers#838816ClinicalTrials.gov
• Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer#845844ClinicalTrials.gov
• Therascreen® KRAS RGQ PCR Kit#889135ClinicalTrials.gov
• Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner#215405HAL (France)
• A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer#897328ClinicalTrials.gov
• Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers#842057ClinicalTrials.gov
• A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation#885449ClinicalTrials.gov
• Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer#913528ClinicalTrials.gov
• Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab#979253ClinicalTrials.gov
• Molecular Mechanisms of KRAS Regulation and Resistance in Pancreatic Ductal Adenocarcinoma#241341EliScholar
• QTX3046 in Patients With KRAS G12D Mutations#837417ClinicalTrials.gov
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies#417550ClinicalTrials.gov
• Emergence of KRAS mosaicism with multiple variants during treatment with alectinib in ALK‑positive metastatic non‑small cell lung cancer: A case report#460839HAL (France)
• DHHC7 palmitoylates KRAS4A and promotes mutant KRAS-driven pancreatic cancers#148841bioRxiv / medRxiv
• A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment#839339ClinicalTrials.gov
• Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation#886723ClinicalTrials.gov
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors#892962ClinicalTrials.gov
• A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification#805511ClinicalTrials.gov
• Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C–mutant non-small cell lung cancer#406912Springer Nature OA